← All tickers

Is AQST Worth Buying in 2026?

Aquestive Therapeutics, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-08-16

Here’s whether Aquestive Therapeutics, Inc. Common Stock (AQST) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: above the 50-day MA (medium-term momentum positive). Concerns: trading below the 200-day MA (long-term downtrend); rising volume on a downtrend (distribution, 1.58x avg). Currently 43.7% off its 52-week high. Score: -1/7.

Ready to act on this? 📈 Trade on Webull

AQST is trading below its 200-day MA ($4.55) — a key warning sign the longer-term trend is under pressure. An RSI of 69.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +3.4% compares to +20.4% for SPY (trailed the market by 17.0%). The current 43.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $10,341 today
vs. S&P 500 (SPY) — same period trailed market by 17.0%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 200-day MA ($4.55)
✓Above 50-day MA ($4.12)
✓RSI(14) neutral zone (30–70) — currently 69.3
✓Positive return (+3.4%)
!Within 10% of period high (−43.7%)
Period Range $4.25
$2.93 $7.55
RSI (14) 69.3
0 · OversoldOverbought · 100

Key Metrics

Price$4.25
Period Return+3.4%
Period High$7.55
Period Low$2.93
Drawdown−43.7%
MA-50$4.12
MA-200$4.55
RSI (14)69.3
Avg Volume (30d)2.6M
vs. SPYtrailed by 17.0%
Return Rank#652 of 1252

Trade AQST

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers